NASDAQ:AVTX Avalo Therapeutics (AVTX) Stock Price, News & Analysis → 4x Better than Bitcoin (From Behind the Markets) (Ad) Free AVTX Stock Alerts $21.75 +17.00 (+357.89%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$16.65▼$34.4650-Day Range$4.10▼$21.7552-Week Range$3.95▼$1,130.40Volume31.53 million shsAverage Volume188,102 shsMarket Capitalization$1.85 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Avalo Therapeutics alerts: Email Address Avalo Therapeutics MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestBearish74.67% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.22Based on 10 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($95.24) to ($16.67) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.37 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Avalo Therapeutics. Previous Next 2.0 Short Interest Percentage of Shares Shorted74.67% of the outstanding shares of Avalo Therapeutics have been sold short.Short Interest Ratio / Days to CoverAvalo Therapeutics has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Avalo Therapeutics has recently increased by 10.34%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAvalo Therapeutics does not currently pay a dividend.Dividend GrowthAvalo Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AVTX. Previous Next 2.9 News and Social Media Coverage News SentimentAvalo Therapeutics has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Avalo Therapeutics this week, compared to 1 article on an average week.Search Interest18 people have searched for AVTX on MarketBeat in the last 30 days. This is an increase of 1,700% compared to the previous 30 days.MarketBeat Follows6 people have added Avalo Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Avalo Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.20% of the stock of Avalo Therapeutics is held by insiders.Percentage Held by Institutions87.06% of the stock of Avalo Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Avalo Therapeutics are expected to grow in the coming year, from ($95.24) to ($16.67) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Avalo Therapeutics is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Avalo Therapeutics is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the Markets4x Better than Bitcoin4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> About Avalo Therapeutics Stock (NASDAQ:AVTX)Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation. The company's drug candidates include AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as Crohn's disease; Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome; and AVTX-008, a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein. It also develops AVTX-803, a L-fucose monosaccharide therapy for treatment of Leukocyte Adhesion Deficiency Type II. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.Read More AVTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AVTX Stock News HeadlinesMarch 29, 2024 | finanznachrichten.deAvalo Therapeutics: Avalo Acquires Anti-IL-1ß mAb and Announces Private Placement Financing of up to $185 MillionMarch 28, 2024 | msn.comMicro-Cap Avalo Therapeutics Stock Rallies As It Snaps AlmataBio For Ex-Eli Lilly Drug For Skin DisorderMarch 29, 2024 | Behind the Markets (Ad)4x Better than Bitcoin4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.March 28, 2024 | investorplace.comWhy Is Avalo Therapeutics (AVTX) Stock Up 326% Today?March 27, 2024 | globenewswire.comAvalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 MillionMarch 26, 2024 | americanbankingnews.comAvalo Therapeutics (NASDAQ:AVTX) Trading Down 2.9%February 26, 2024 | finance.yahoo.comAvalo (AVTX) to Report Q4 Earnings: What's in the Cards?January 2, 2024 | benzinga.comAvalo Therapeutics Stock (NASDAQ:AVTX) Dividends: History, Yield and DatesMarch 29, 2024 | Behind the Markets (Ad)4x Better than Bitcoin4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.December 27, 2023 | msn.comAvalo Therapeutics announces a 1-for-240 reverse stock splitDecember 27, 2023 | finance.yahoo.comAvalo Therapeutics Announces 1-for-240 Reverse Stock SplitDecember 18, 2023 | finance.yahoo.comAvalo Therapeutics, Inc. (AVTX) stock forecast and price targetDecember 7, 2023 | finanznachrichten.deAvalo Therapeutics: Avalo Encourages Stockholders to Vote FOR the Reverse Stock SplitDecember 7, 2023 | finance.yahoo.comAvalo Encourages Stockholders to Vote FOR the Reverse Stock SplitNovember 11, 2023 | benzinga.comAvalo Therapeutics Stock (NASDAQ:AVTX) Earnings Dates and Earning CallsNovember 9, 2023 | morningstar.comAvalo Therapeutics Inc AVTXNovember 9, 2023 | finance.yahoo.comAvalo Therapeutics Inc (AVTX) Announces Q3 2023 Financial Results and Strategic AdvancesNovember 9, 2023 | finance.yahoo.comAvalo Reports Third Quarter 2023 Financial Results and Provides Business UpdatesOctober 31, 2023 | finance.yahoo.comAvalo Completes Divestiture of AVTX-800 SeriesSeptember 27, 2023 | finance.yahoo.comBestGrowthStocks.com Issues a Comprehensive Analysis of Avalo TherapeuticsSeptember 26, 2023 | benzinga.comWhy Avalo Therapeutics Stock Is Up TodaySeptember 22, 2023 | benzinga.comWhat's Going On With Avalo Therapeutics (AVTX) Stock?September 18, 2023 | benzinga.comWhy Rubicon Technologies Shares Are Trading Lower By Over 7%; Here Are 20 Stocks Moving PremarketSeptember 13, 2023 | benzinga.comWhy Eiger BioPharmaceuticals Shares Are Trading Lower By 52%? Here Are Other Stocks Moving In Wednesday's Mid-Day SessionSeptember 13, 2023 | msn.comAvalo drops three rare disease assets amid ongoing challengesSeptember 13, 2023 | benzinga.comWhy Mainz Biomed Shares Are Trading Higher By 17%; Here Are 20 Stocks Moving PremarketSeptember 12, 2023 | marketwatch.comAvalo Therapeutics Shares Rise 53% After Deal to Divest Certain AssetsSee More Headlines Receive AVTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avalo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/02/2022Today3/29/2024Next Earnings (Estimated)4/03/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AVTX CUSIPN/A CIK1534120 Webwww.avalotx.com Phone(410) 522-8707FaxN/AEmployees20Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($616.6667) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-41,660,000.00 Net Margins-1,475.02% Pretax Margin-1,473.60% Return on EquityN/A Return on Assets-107.83% Debt Debt-to-Equity RatioN/A Current Ratio2.11 Quick Ratio2.11 Sales & Book Value Annual Sales$18.05 million Price / Sales0.11 Cash FlowN/A Price / Cash FlowN/A Book Value($275.57) per share Price / Book-0.08Miscellaneous Outstanding Shares90,000Free Float85,000Market Cap$1.96 million OptionableNot Optionable Beta0.69 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Garry A. Neil M.D. (Age 70)Chairman of the Board, President & CEO Comp: $601.9kMr. Christopher Ryan Sullivan (Age 40)CFO & Head of Investor relations Comp: $466.94kDr. Solomon H. Snyder M.D. (Age 85)Founder and Chairman of Scientific Advisory Board Dr. Barbara S. Slusher Ph.D. (Age 59)Founder and Member of Scientific Advisory Board Dr. Lisa Hegg Ph.D.Senior Vice President of Program Management, Corporate Infrastructure & Clinical OperationsMs. Colleen MatkowskiSenior Vice President of Global Regulatory Affairs & Quality AssuranceDr. Dino C. Miano Ph.D.Senior Vice President of CMC & Technical OperationsMore ExecutivesKey CompetitorsTransCode TherapeuticsNASDAQ:RNAZAthersysNASDAQ:ATHXGRI BioNASDAQ:GRIGalmed PharmaceuticalsNASDAQ:GLMDRevelation BiosciencesNASDAQ:REVBView All CompetitorsInsidersArmistice Capital, LlcSold 11,442 sharesTotal: $1.68 M ($146.40/share)Caissa Capital Management Ltd.Bought 8 shares on 6/20/2023Total: $7,948.80 ($993.60/share)Caissa Capital Management Ltd.Bought 12 shares on 6/16/2023Total: $11,232.00 ($936.00/share)Caissa Capital Management Ltd.Bought 25 shares on 6/14/2023Total: $20,880.00 ($835.20/share)Caissa Capital Management Ltd.Bought 8 shares on 6/12/2023Total: $8,332.80 ($1,041.60/share)View All Insider Transactions AVTX Stock Analysis - Frequently Asked Questions Should I buy or sell Avalo Therapeutics stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avalo Therapeutics in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" AVTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AVTX, but not buy additional shares or sell existing shares. View AVTX analyst ratings or view top-rated stocks. How have AVTX shares performed in 2024? Avalo Therapeutics' stock was trading at $9.10 at the start of the year. Since then, AVTX stock has increased by 139.0% and is now trading at $21.75. View the best growth stocks for 2024 here. Are investors shorting Avalo Therapeutics? Avalo Therapeutics saw a increase in short interest in March. As of March 15th, there was short interest totaling 67,200 shares, an increase of 10.3% from the February 29th total of 60,900 shares. Based on an average daily trading volume, of 51,300 shares, the days-to-cover ratio is presently 1.3 days. View Avalo Therapeutics' Short Interest. When is Avalo Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 3rd 2024. View our AVTX earnings forecast. How were Avalo Therapeutics' earnings last quarter? Avalo Therapeutics, Inc. (NASDAQ:AVTX) announced its earnings results on Wednesday, March, 2nd. The company reported ($460.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($432.00) by $28.80. When did Avalo Therapeutics' stock split? Shares of Avalo Therapeutics reverse split on the morning of Friday, December 29th 2023. The 1-240 reverse split was announced on Friday, December 29th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, December 29th 2023. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split. Who are Avalo Therapeutics' major shareholders? Avalo Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Armistice Capital, Llc, Caissa Capital Management Ltd, Christopher Ryan Sullivan, Garry Arthur Neil, H Jeffrey Wilkins and Schond L Greenway. View institutional ownership trends. How do I buy shares of Avalo Therapeutics? Shares of AVTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AVTX) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 Media“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyOnly a fool would buy Nvidia today… Porter & CompanyAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avalo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.